New Two-Pronged attack on aggressive stomach cancer
NCT ID NCT07315035
Summary
This study is testing whether adding a new immunotherapy drug called QL1706 to standard chemotherapy before stomach cancer surgery works better than chemotherapy alone. The goal is to shrink tumors more effectively before surgery, potentially leading to better long-term outcomes. The trial will enroll 74 adults with a specific aggressive type of stomach cancer that hasn't spread to distant organs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.